Numerous studies have demonstrated the ability of exosomes to repair cardiac tissue after myocardial infarction (MI), as well as the benefits of cell therapy. The objective of the study, “Experimental, Systems, and Computational Approaches to Understanding the MicroRNA-Mediated Reparative Potential of Cardiac Progenitor Cell-Derived Exosomes From Pediatric Patients,” by Udit Agarwal et al., was to evaluate the role of donor age and hypoxia in human pediatric cardiac progenitor cell-derived exosomes. The model used was a rat model of ischemia-reperfusion injury.
The following section explores the mechanisms proposed to support cardiac repair after myocardial infarction and provides the context for the study’s focus on exosome-mediated effects.
By América Torres
Improving Cardiac Function After a Myocardial Infarction
Cardiac Progenitor Cells (CPCs) were discovered in 2003. Since then, multiple types of therapies have been investigated to improve cardiac function after myocardial infarction and prevent heart failure. Over the past two decades, stem cell therapy has become an exciting option to improve cardiac remodeling after MI. Although initially thought to result directly from the cells themselves, most researchers now consider paracrine mechanisms to be a main benefit of cell therapy.
Key Findings on Pediatric Cardiac Progenitor Cell-Derived Exosomes
Exosome Size and Cardiac Progenitor Cells
The authors of the trial mention that they found that human pediatric cardiac progenitor cells generate exosomes of 120±12 nm, which coincides with the information that had already been provided by other works.
Exosomes as a Cell-Free Approach to Cardiac Repair
It is possible to take advantage of many of the benefits of cell therapy without them. This is important for sources such as embryonic progenitor cells, which have risks o tumorigenicity, as they did not show tumorigenicity of the exomes and that may help dissipate concerns for many other cells.
Exosome Uptake by Cardiac Cells
This study also demonstrated that the three main types of cardiac cells (fibroblasts, endothelial and cardiomyocytes) internalize human pediatric CPCs.
Differences in Exosome Uptake Among Cardiac Cells
It is necessary to mention that there were specific differences among the cells. Fibroblasts occupied the majority of exosomes, followed by endothelial cells; however, cardiomyocytes minimally internalized exosomes.
Cardiac Myocyte Internalization of Exosomes
While several trials by other authors suggest that myocytes produce exosomes, this trial offered the first report of cardiac myocytes internalizing exosomes. Despite this, many studies show improvements in cardiac function without any effect on the myocytes themselves.
Exosome-Mediated Effects on Cardiomyocyte Survival
The authors believe that their finding that exosomes are not absorbed by cardiomyocytes may open the possibility of considering whether actions on local fibroblasts, or perhaps even infiltrating inflammatory cells, could improve myocyte survival. They do not rule out the possibility that fibroblasts reprogrammed with exosomes and endothelial cells modulate cardiomyocyte function through the secretion of potent endogenous exosomes, absorbed by myocytes.
New Data on Pediatric Cardiac Progenitor Cells
It is well known that stem cell therapy after MI offers beneficial paracrine signaling thanks to exosomes. It is also known that children have Cardiac Progenitor Cells that can be useful, although the function of these varies greatly depending on the age of the donor. In fact, it is still unknown how the child’s age and hypoxia affect the quality of the exosome and its potential to repair the heart of the MI patient. This study helped to shed some light on these and other issues, because it provided the following information:
- Pediatric Cardiac Progenitor Cells secrete exosomes with a very different microRNA content.
- Exosomes of newborns are restorative, and their effectiveness decreases with age; the hypoxic precondition of cells restores exosomal function.
- Computer models are capable of creating predictive models based on microRNA content. They can also predict the function of exosomes derived from other cells. This may lead to the identification of new microRNA functions.
These findings highlight the potential of microRNA-mediated cardiac repair after myocardial infarction. They also show how donor age and the cellular environment may influence the reparative properties of cardiac progenitor cell-derived exosomes.
Cardiac Rehabilitation After Myocardial Infarction
At SCHILLER, we know that cardiac rehabilitation is essential for the recovery of patients who have suffered a myocardial infarction. That’s why we offer a range of solutions for cardiac stress testing and rehabilitation, including medical ergometers and stress testing systems designed for cardiology and rehabilitation settings.
Interested in our cardiac rehabilitation solutions? Book a personalized demo and see how they fit your clinical workflow.
FAQ About MicroRNA, Exosomes, and Cardiac Repair
What are pediatric cardiac progenitor cell-derived exosomes?
Pediatric cardiac progenitor cell-derived exosomes are small extracellular vesicles released by human cardiac progenitor cells obtained from pediatric patients. They contain biologically active cargo, including microRNAs, and may mediate paracrine communication between cardiac cells. Their potential to support cardiac repair has been investigated in preclinical models of myocardial ischemia–reperfusion injury, not yet established as a clinical therapy.
How might microRNAs in exosomes contribute to cardiac repair?
MicroRNAs carried by exosomes can regulate gene expression in recipient cells and influence pathways involved in cell survival, angiogenesis, fibrosis, and cardiac remodeling. The study identified distinct microRNA profiles in pediatric cardiac progenitor cell-derived exosomes and used computational modeling to associate these profiles with functional outcomes. However, the study did not establish that individual microRNAs were solely responsible for the reparative effects.
Does donor age affect the reparative potential of cardiac progenitor cell-derived exosomes?
Yes. In a preclinical rat model of ischemia–reperfusion injury, exosomes derived from neonatal cardiac progenitor cells improved cardiac function under both normoxic and hypoxic culture conditions. Exosomes from older pediatric donors showed less reparative activity under normoxia but regained activity after hypoxic conditioning. These findings suggest that donor age can influence exosomal microRNA content and biological activity.
Can hypoxic preconditioning improve the therapeutic potential of pediatric cardiac progenitor cell-derived exosomes?
Hypoxic preconditioning could partially restore the reparative activity of exosomes derived from older pediatric cardiac progenitor cells. It was also associated with improved angiogenesis, reduced fibrosis, and changes in exosomal microRNA profiles in preclinical models. These findings support hypoxia as a potential strategy for optimizing exosome production, but they do not yet demonstrate clinical efficacy in patients.
Which cardiac cells internalize exosomes derived from pediatric cardiac progenitor cells?
In vitro confocal imaging showed that fibroblasts, endothelial cells, and cardiomyocytes can internalize pediatric cardiac progenitor cell-derived exosomes. Uptake differed by cell type: fibroblasts showed the greatest uptake, endothelial cells showed intermediate uptake, and cardiomyocytes showed minimal internalization. The study suggested that effects on fibroblasts and endothelial cells may contribute substantially to cardiac repair.